Devyser Diagnostics

Devyser Diagnostics EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Devyser Diagnostics (DVYSR.ST) as of Oct 20, 2026 is 10.60 M SEK. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -58.30 M SEK — a change of -118.18% (higher).

EBITDA

10.60 MSEK

YoY

-118.18%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Devyser Diagnostics is 2025 10.60 M SEK. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Devyser Diagnostics was 2024 -58.30 M SEK. It decreases by -118.18% higher compared to the previous year.

The Devyser Diagnostics EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-3.51 M SEK
Jan 1, 2019
8.65 M SEK
Jan 1, 2020
-6.96 M SEK
Jan 1, 2021
-21.56 M SEK
Jan 1, 2022
-54.95 M SEK
Jan 1, 2023
-56.50 M SEK
Jan 1, 2024
-58.30 M SEK
Jan 1, 2025
10.60 M SEK
The Devyser Diagnostics EBITDA history
YEAREBITDAYoY
10.60 MSEK-118.18%
-58.30 MSEK+3.19%
-56.50 MSEK+2.82%
-54.95 MSEK+154.83%
-21.56 MSEK+209.99%
-6.96 MSEK-180.43%
8.65 MSEK-346.38%
-3.51 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Devyser Diagnostics Stock analysis

What does Devyser Diagnostics do? Devyser Diagnostics AB develops and sells genetic testing kits for routine diagnostics, targeting hereditary diseases, oncology, and post-transplantation monitoring. The company offers products like Devyser Thrombophilia assay and Devyser Resolution XY, which analyze DNA for diagnosing genetic conditions and guiding cancer treatment. These kits are sold directly to end customers or through hired distributors across more than 45 countries, with nearly 30 products developed since inception. The firm generates revenue through direct sales and distributor partnerships, focusing on healthcare providers and laboratories that require genetic testing solutions. Its products are used in complex DNA analysis for diagnosing hereditary disorders and optimizing cancer therapies, serving a global market in over 45 countries without relying on third-party brands or external partnerships beyond its own product portfolio. Devyser Diagnostics AB's business model centers on selling its proprietary genetic testing kits, with no mention of additional services or third-party collaborations. The company's revenue streams are derived solely from product sales, targeting healthcare institutions that utilize DNA testing for diagnostic and therapeutic purposes in specialized medical fields. Devyser Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Devyser Diagnostics stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Devyser Diagnostics is 10.60 M SEK in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Devyser Diagnostics changed from -58.30 M SEK to 10.60 M SEK, representing a -118.18% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Devyser Diagnostics since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Devyser Diagnostics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Devyser Diagnostics

All Key Metrics — Devyser Diagnostics